Target Information
General Information of This Target
Target ID | PATR0YTGZR |
|||||
---|---|---|---|---|---|---|
Target Name | Nicotinamide phosphoribosyltransferase (NAMPT) |
|||||
Gene Name | NAMPT |
|||||
Gene ID | ||||||
Synonym | PBEF, PBEF1; Pre-B-cell colony-enhancing factor 1; Visfatin |
|||||
Sequence |
MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFY
GLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVP EGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETS GNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGY SVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIV SRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINT LQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVAD PNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNA QLNIELEAAHH Click to Show/Hide
|
|||||
Family | the NAPRTase family |
|||||
Function |
Catalyzes the condensation of nicotinamide with 5- phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-BMAL1 heterodimer from NAD-dependent SIRT1- mediated suppression.
Click to Show/Hide
|
|||||
Uniprot Entry | ||||||
HGNC ID | ||||||
KEGG ID |
Full List of The ADC Related to This Target
Clinical candidate
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
Alpha-human dectin-1-pam3 conjugate |
Undisclosed |
CLEC7A |
NAMPT toxophore |
Undisclosed |
[1] |
Investigative
ADC Info | ADC Name | Antibody | Antigen | Payload | Linker | Ref |
---|---|---|---|---|---|---|
HER2-EC4 DAR7.8 |
Anti-human HER2 mAb |
ERBB2 |
NAMPT inhibitor 5 |
Open-chain glycine maleimide |
[2] | |
B7H3-EC3 DAR4.1 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 4 |
Mc-Val-Ala |
[2] | |
B7H3-EC3 DAR7.8 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 4 |
Mc-Val-Ala |
[2] | |
C4.4A-EC4 |
Anti-human LYPD3 mAb |
LYPD3 |
NAMPT inhibitor 5 |
Open-chain glycine maleimide |
[2] | |
HER2-EC5 |
Anti-human HER2 mAb |
ERBB2 |
NAMPT inhibitor 6 |
Open-chain glycine maleimide-PEG |
[2] | |
HER2-EC4 DAR2.7 |
Anti-human HER2 mAb |
ERBB2 |
NAMPT inhibitor 5 |
Open-chain glycine maleimide |
[2] | |
HER2-EC3 |
Anti-human HER2 mAb |
ERBB2 |
NAMPT inhibitor 4 |
Mc-Val-Ala |
[2] | |
HER2-EC1 |
Anti-human HER2 mAb |
ERBB2 |
NAMPT inhibitor 4 |
Maleimido-caproyl |
[2] | |
C4.4A-EC5 |
Anti-human LYPD3 mAb |
LYPD3 |
NAMPT inhibitor 6 |
Open-chain glycine maleimide-PEG |
[3] | |
C4.4A-EC3 |
Anti-human CD276 mAb |
LYPD3 |
NAMPT inhibitor 4 |
Mc-Val-Ala |
[2] | |
C4.4A-EC2 |
Anti-human LYPD3 mAb |
LYPD3 |
NAMPT inhibitor 6 |
Maleimido-caproyl |
[2] | |
C4.4A-EC1 |
Anti-human LYPD3 mAb |
LYPD3 |
NAMPT inhibitor 4 |
Maleimido-caproyl |
[2] | |
B7H3-EC5 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 6 |
Open-chain glycine maleimide-PEG |
[2] | |
B7H3-EC4 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 5 |
Open-chain glycine maleimide |
[2] | |
B7H3-EC2 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 6 |
Maleimido-caproyl |
[2] | |
B7H3-EC1 |
Anti-human CD276 mAb |
CD276 |
NAMPT inhibitor 4 |
Maleimido-caproyl |
[2] | |
CD206-NAMPT inhibitor-based antibody drug conjugate |
Undisclosed |
MRC1 |
NAMPT toxophore |
Undisclosed |
[4] |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.